Sunitinib, an approved second-line therapy drug for imatinib-resistant GIST patients, potently inhibits KIT of ATP-binding pocket mutants to overcome some imatinib-resistant mutants [10]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.